Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituxan in Polyneuropathies Associated With Serum IgM Autoantibodies
NCT00006072Phase 2
Key facts
- Status
- Unknown
- Sponsor
- National Center for Research Resources
- Modality
- Monoclonal Antibodies
- Drugs
- rituximab
- Conditions
- peripheral neuropathy
01
Overview
Phase 2, open-label, single-arm trial of rituximab in peripheral neuropathy, sponsored by National Center for Research Resources. Primary endpoints: Muscle strength at 1 year and Serum IgM autoantibodies at 1 year. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Rituxan
Rituxan for two treatments one week apart and then individual treatments every 10 weeks for one year.
03
Who it enrols
Patients with characteristic peripheral neuropathy and high titers of serum anti-GM1 or anti-MAG antibodies who have previously received one course of Rituxan.
04
Endpoints
Primary
Muscle strength
Serum IgM autoantibodies
Beyond the preview
Go deeper on NCT00006072.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006072.